Substituted Morpholine Derivatives for CNS Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for central nervous system (CNS) disorders using 2-((2-ethoxyphenoxy)methyl)morpholine are associated with numerous side effects, necessitating the development of derivatives that retain pharmacologic properties while minimizing adverse reactions.
Innovation Solution
Synthesis of novel derivatives of substituted morpholines, specifically targeting the derivatization of the amine group in 2-((2-ethoxyphenoxy)methyl)morpholine to produce chemically stable compounds that can be used in pharmaceutical compositions for CNS disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 2-((2-ethoxyphenoxy)methyl)morpholine is used to treat CNS disorders, then therapeutic efficacy is achieved, but numerous side effects occur
Solution Approach 1:
The patent modifies the chemical structure of 2-((2-ethoxyphenoxy)methyl)morpholine by changing parameters at specific positions (R1, R2, R3-R14 substituents) to create derivatives that maintain therapeutic efficacy while reducing side effects. This involves systematic variation of chemical groups at different positions in the morpholine molecule to optimize the balance between efficacy and tolerability.
Solution Approach 2:
The patent creates composite molecular structures by combining the morpholine core with various substituent groups (alkyl, aryl, heteroaryl, heterocyclyl, pyridyl, etc.) at multiple positions. These composite derivatives integrate different functional groups to achieve both therapeutic activity and reduced adverse effects through synergistic structural modifications.
2Object-generated harmful factors
If derivatives of substituted morpholines are synthesized to reduce side effects, then tolerability improves, but chemical stability may be compromised
Solution Approach 1:
The patent applies local quality modification by introducing specific substituent types at particular positions in the morpholine molecule. Different regions of the molecule are modified with different functional groups (e.g., electron-donating or electron-withdrawing groups at R1, R2, R3-R14) to locally adjust electronic properties while maintaining overall molecular stability and pharmacological activity.
Data Source
AI summary
A compound of Formula I includes a stereoisomer thereof and/or a salt thereof; wherein R1 is a substituted alkane group, a heterocylic group, or a pyridine group; X is hydrogen, a halogen, an amino acid residue, a substituted amino acid residue, an alkyl group, or an ester. Such compounds may be used in pharmaceutical compositions and for the treatment of central nervous system (CNS) disorders: